We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- What goes wrong in cancer
- Next generation sequencing (NGS)
- Transcriptomic analysis & cancer
- Advanced precision medicine
- Follicular lymphoma (FL)
- The key challenges in FL management
- Genetic landscape of FL & transformed FL (tFL)
- It’s not all about t(14;18)
- Using mutations to identify high risk patients
- Mutational status: not the only outcome predictor
- An integrated model
- Changing the face of FL therapy
- CREBBP mutations
- Identification of mutations in mTORC1
- RRAGC mutations activate mTORC1 pathway
- TNFRSF14 (HVEM) mutations
- EZH2 mutations promote lymphomagenesis
- EZH2 inhibitors: precision medicine in practice
- Actionable biological pathways in FL
- Emerging challenges in precision therapy of FL
- FL transformation: no simple genetic explanation
- Spatial intra-tumour heterogeneity in FL
- Intra-tumor heterogeneity at transformation
- ctDNA profiling
- CPCs: long living and can give rise to lymphoma
- Two modes of genetic evolution present in FL
- Current view of FL disease progression
- Summary
- Acknowledgements
Topics Covered
- Technological advances in precision medicine
- Follicular lymphoma and its genetic landscape
- Advances in patient stratification at diagnosis
- Novel therapeutic strategies
- Clonal evolution and heterogeneity
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Korfi, K. and Fitzgibbon, J. (2017, November 30). Germinal centre lymphomas: advances in diagnostic and therapeutic intervention [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 7, 2024, from https://doi.org/10.69645/UEQS9022.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Koorosh Korfi has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Prof. Jude Fitzgibbon, Consultant : Epizyme Speaker's Bureau: Gilead, Janssen, Roche Grant/Research Support (Principal Investigator): Epizyme
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
I'm Koorosh Korfi, I'm a senior scientist at Barts Cancer Institute in London,
and I'm also part of a UK-wide precision medicine for aggressive lymphoma consortium.
The title of this lecture,
is "Advances in Diagnostic and Therapeutic Intervention in Germinal Center Lymphomas",
and I will be using follicular lymphoma as an example.
This lecture has been co-authored by myself and Professor Jude Fitzgibbon.
0:26
What I'm going to talk to you about will
be technological advances that help us drive precision medicine,
and with that, I would delve into follicular lymphoma,
hematologic malignancy and what we know about the genetic landscape of this disease.
And following that, I'll be talking about the advances
we've made in patient stratification at diagnosis,
as well as, the Novel therapeutic strategies,
as part of this precision medicine approach.
I would be also talking briefly about the Clonal evolution and
heterogeneity paradigms as ever-evolving challenges in cancer treatment and management.
0:59
Since, follicular lymphoma is a hematologic malignancy,
I'd like to reposition ourselves to think back
about cancer as a whole and what goes wrong in cancer.
The cellular phenotype and the function of our tissues and organs is
tightly regulated by four different layers of information.
As you can see here, schematically represented, in essential for our cells and in our nuclei,
we have chromosomal structures,
which are made of our genetic code on DNA molecules, wrapped in,
what we call epigenetic marks which
consist of histone modifications and DNA methylation,
that dictate the accessibility of this genetic code
for downstream expression of our coding genes.
And you can see the next level of inflammation,
is transcription which encodes messenger RNAs and following that,
the final layer of information comes in the format
of proteins which are translated from mRNAs.
And you can imagine any aberrations in any of
these four layers of information can result in a disease such as cancer.
On the right-hand side, you can see what changes the level of
DNA can we expect information of disease, such as cancer.
So, we have 20,000 and so coding genes in our DNA.
That only accounts for two percent of our genome, but more interestingly,
the rest of our genome,
98 percent of that is a non-coding genome that is regulating these coding genes,
and also encodes for more than 20,000 non-coding RNAs.
So, you can see the complexity of
genetics in a single-cell and what can go wrong in the case of a disease.
But that's not everything,
and we know that abnormalities at the level of transcription can
also result in abnormal expression of these genes.
And also, abnormalities at the level of epigenetics such as,
DNA methylation and histone modifications can
also make differences in accessibility of
this genetic material for downstream expression of these genes.
And of course, at the final layer we can also have abnormalities of
the protein folding and post-translational modifications.
This is a simplistic view of a lot of things that can go wrong in cancer.
So really the question is,
how can we identify these abnormalities in a disease
setting such as cancer and in an individual?
And basically to answer that,
we need to know what tools do we have.
It's been fascinating over the past decade how far we've come
Hide